98%
921
2 minutes
20
Background: Fractional flow reserve (FFR) and the instantaneous wave-free ratio (iFR) identify arteries that benefit from percutaneous coronary intervention (PCI). FFR or iFR gradients on pullback are often used to predict the physiological result (FFR or iFR), but this approach is unvalidated.
Objectives: The aim of this study was to compare the accuracy of FFR, iFR and FFR (a mathematical solution incorporating interaction between lesions) for predicting post-PCI physiology in serial or diffuse disease.
Methods: Patients with a focal target lesion and either a second focal lesion or a diffusely diseased segment in the same vessel were randomized to FFR- vs iFR-guided PCI (ISRCTN18106869). FFR and iFR pullbacks were performed, with operators blinded to one modality. Following target lesion PCI, FFR and iFR were remeasured. The primary outcome was the error in predicted post-PCI physiology compared with actual values.
Results: A total of 87 patients were randomized to FFR (n = 45) or iFR (n = 42). Median FFR and iFR were 0.70 (Q1-Q3: 0.62 to 0.78) and 0.81 (Q1-Q3: 0.68 to 0.90) at baseline and 0.82 (Q1-Q3: 0.74 to 0.87) and 0.89 (Q1-Q3: 0.83 to 0.93) after target lesion PCI. The predictive errors were 12% (6% to 17%) for FFR, 4% (0% to 9%; P < 0.001) for iFR, and -5% (-18% to 8%; P = 0.427) for FFR. Significant residual disease was missed in 36% of cases with FFR, 34% with iFR, and 14% with FFR.
Conclusions: FFR and iFR pullback gradients overestimate the benefit of target lesion PCI and can miss residual ischemia in one-third of patients. FFR or iFR should be routinely repeated post-PCI in serial disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcin.2025.05.033 | DOI Listing |
Catheter Cardiovasc Interv
September 2025
Royal North Shore Hospital, St Leonards, Australia.
Background: Invasive coronary physiology including fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), and coronary flow reserve (CFR) are guideline-endorsed tools to guide the management of coronary artery disease (CAD). Complex factors impact and confound these assessments, and discordance between modalities complicates clinical management. iEquate is a prospective observational trial that combines multi-modality coronary physiology and optical coherence tomography (OCT) to identify the determinants of pressure-wire derived myocardial ischemia and iFR-FFR discordance.
View Article and Find Full Text PDFAm J Cardiol
September 2025
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy. Electronic address:
Introduction: A myocardial bridge (MB) is a condition where a segment of an epicardial coronary artery passes through the myocardial muscle. While traditionally regarded as benign, MBs have been associated with various cardiovascular conditions. Therefore, assessing their hemodynamic impact is crucial for informed treatment decisions.
View Article and Find Full Text PDFAm J Cardiol
September 2025
Faculty of Medicine, Istanbul University, Istanbul, Turkey; Department of Cardiology, Acibadem International Hospital, Istanbul, Turkey. Electronic address:
Although physiologic evaluation (e.g., fractional flow reserve) of intermediate lesions is well established in other coronary arteries, the left main coronary artery (LMCA) exhibits diagnostic challenges, hindering development of physiology-based decision-making algorithms.
View Article and Find Full Text PDFJ Clin Med
July 2025
Department of Cardiology, Methodist Hospital, La Porte, IN 46350, USA.
Quantitative Flow Ratio (QFR) is a novel, wire-free, and hyperemia-free physiological assessment for guiding Percutaneous Coronary Intervention (PCI), which may offer advantages over traditional angiography-guided PCI. This systematic review with meta-analysis compares clinical outcomes after one year in patients who underwent QFR-guided versus angiography-guided PCI. This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered on 4 November 2024 in PROSPERO (ID: CRD42024609799).
View Article and Find Full Text PDF